AtonRa Partners’s Acadia Pharmaceuticals ACAD Stock Holding History

AtonRa Partners’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-26,315	Closed	-$371K	–	115
2022 Q2	$371K	Buy	+26,315	New	+$491K	0.34%	114
2021 Q3	–	Sell	-53,527	Closed	-$1.31M	–	116
2021 Q2	$1.31M	Buy	53,527 +5,373	+11%	+$121K	0.48%	77
2021 Q1	$1.24M	Sell	48,154 -7,509	-13%	-$331K	0.55%	74
2020 Q4	$2.98M	Buy	+55,663	New	+$2.76M	1.46%	21

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

AtonRa Partners's ACAD Position: Q3 2022 in Review

AtonRa Partners sold out of Acadia Pharmaceuticals (ACAD) in Q3 2022, closing a stake of 26,315 shares — an estimated $371K sold.

AtonRa Partners first reported a position in ACAD in Q4 2020 and held it in 4 quarters. The position peaked at $2.98M in Q4 2020. 223 funds tracked by Wall St. Rank hold ACAD as of Q3 2022.

AtonRa Partners reported no remaining Acadia Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
AtonRa Partners sold 26,315 Acadia Pharmaceuticals shares in Q3 2022, an estimated $371K.
AtonRa Partners first reported a position in Acadia Pharmaceuticals in Q4 2020 and held it in 4 quarters.
AtonRa Partners's Acadia Pharmaceuticals position peaked at $2.98M in Q4 2020.
223 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2022.

Based on AtonRa Partners's 13F filing for Q3 2022, filed 14 Nov 2022.